Hindustan Foods Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

4 Ganesh Argekar, Mayank Samdani, Sameer Kothari, Vimal Solanki

Analysts

10 Abhishek Mathur, Abneesh Roy, Akhil Parekh, Ankit Dharamshi, Faisal Hawa, Mayur Parkeria, Rahul, Riddhansh Chandak, Surbhi Soni, Virat Pansuriya

Financials & KPIs

Geographic & Segment Commentary

Home & Personal Care: Operating at maximum capacity across all sites with record quarterly performance. Aurangabad personal care facility integration completed and running seamlessly; brownfield expansion at Silvassa expected to commence production in Q2 FY27, greenfield Lucknow facility on track for commissioning later this year. Management noted materially improved demand traction in HPC versus three months ago.

Food & Beverages: Coimbatore, Nashik, and Mysore units operating at record production levels. Beverage division had an excellent season and is flagged as a major growth avenue. Entering Greek yogurt category with new Goa facility. Company is adding new customers across ice cream and cone manufacturing at Nashik to improve asset utilization.

Ice Cream: Delivered another strong quarter backed by robust summer season and record production volumes. Successfully commissioned state-of-the-art Panipat facility during the quarter; expanding capacities to cater to growing customer demand.

Healthcare: Added new customers across syrup, tablets, and lozenges; progressing Ayurvedic wellness expansion at Baddi. Initiated Class 3 medical devices certification at Chennai facility to support entry into regulated international markets (EU/UK). Baddi facility expected to reach 100% capacity utilization in next 6-12 months with two new MNC customers in commercial production.

Footwear: Experienced temporary cost pressures — ₹6 crores hit from Middle East crisis-driven raw material/freight inflation and Haryana minimum wage hike (~30%). Order book full from Q2 FY27 through year-end; capacity utilization expected at 80-90% from August. New customer wins on domestic and MNC fronts; South India units now have full order books. Division expected to return to profitability in coming months and "pay off" in H2 FY27.

Company-Specific & Strategic Commentary

Project Pipeline & Execution: Management disclosed project pipeline of ~₹1,000 crores under discussion, on top of ₹500+ crores invested in FY26 and ~₹500+ crores planned for FY27. Policy remains to announce CapEx only after signing; company maintains 1:1 debt-equity ratio funding model with threshold ROCE of 18% on new projects.

Backward Integration: Attempting to replicate cone/stick manufacturing success — existing customers now sourcing these inputs, and company has cross-sold to non-CM customers. Actively exploring further backward integration opportunities to increase wallet share.

Exports & International: US personal care order (from US brand, mentioned two quarters ago) is development-complete and ready to ship but on hold due to tariff/freight uncertainty. Dr. Scholl's portfolio currently exported to UK, EU, Australia, New Zealand, Japan. Exploring India-UK and India-EU FTAs for footwear; Middle East export talks on hold due to geopolitical crisis.

Silvassa Flood Disruption: Facility received ~10 feet of water in July's record rainfall. Production partially restored within a week; expected fully operational by end of August. Facility adequately insured; no material impact on long-term operations or growth plans.

GST Duty Inversion: Continues to impact cash flows in some business units; management expects profitability (EBITDA/PAT) growth to outpace revenue growth. Some contracts moving to customer-supplied raw material model, which will further skew revenue-to-profit growth ratios.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Footwear Cost Mechanics & Pass-Through

• Question: How does the pass-through work in footwear given season-fixed pricing? Is this a structural risk? (Abhishek Mathur)
• Answer: Shoe industry fixes prices 6-8 months to a year in advance; raw material and packaging rates are also fixed. Brands don't absorb cost changes mid-season. ~50% of raw materials (fabrics, laces, eyelets, soles, labels) are imported. The inertia works both ways — if prices fall, the company benefits. Normal inflation is baked into pricing; black swan events (Middle East crisis) are not. This is unique to shoes; only shoe business, not other divisions. (Ganesh Argekar)
• Question: EBITDA/EBIT impact quantification and whether PAT should trend to lower end of guidance? (Virat Pansuriya)
• Answer: Impact is ~₹6 crores total for Q1, with ₹3 crores from wage increases. Guidance of ₹200-220 crores reaffirmed; too early to revise, will revisit in a couple of quarters if needed. (Mayank Samdani, Sameer Kothari)

CapEx Breakup & Beverage Returns

• Question: Breakup of ₹340 crores new projects? And is it fair to assume 100% utilization in FY28 with 18% ROCE → ₹40 crores bottom-line addition? (Surbhi Soni)
• Answer: Breakup — F&B ₹210 crores across Coimbatore, Mysuru, Goa, Aurangabad, Hyderabad (beverage); ice cream ₹80 crores at Panipat; HPC ₹50 crores at Lucknow (bar and liquid line). Beverage units come online by Dec-Jan to catch the season; most projects are anchor-tenant underwritten, so utilization shouldn't be a problem. The 18% is on EBIT, not PAT; with 1:1 debt-equity there will be interest outflow. (Ganesh Argekar, Mayank Samdani)

Footwear Capacity and Order Book

• Question: Where is footwear capacity utilization? Is the order book from existing or new customers? (Surbhi Soni)
• Answer: Q1 utilization was poor due to material availability/freight disruptions. From August, 80-90% utilization; trying to reach 100% but labor-intensive ramp-up requires hiring. Full order book from new customer wins (domestic + MNCs), existing customers increasing orders, some customers who stopped during acquisition transition have returned, and South units have full order books. Journey took nearly two years, but shoe business should start paying off in H2 FY27. (Sameer Kothari)

Customer Perception & Contract Manufacturing Scale

• Question: How has customer perception changed with scale? Is negotiation power better? (Akhil Parekh)
• Answer: HFL defined FMCG contract manufacturing in India as the largest, most diversified player. Customers recognize execution at scale across geographies and categories (liquid detergents to ice creams). Five dedicated BUs with experienced CEOs strengthen confidence. Pipeline of ~₹1,000 crores under discussion signals customer trust. Company beginning to mirror a national airline — shutting down for even a few days would cause trouble across the FMCG industry. (Sameer Kothari)

Exports & International Expansion

• Question: Update on US big-box retailer discussions? (Akhil Parekh)
• Answer: Discussions ongoing; US personal care brand order (mentioned two quarters ago) is development-complete and ready to ship but on hold due to tariff ambiguity. Also exploring India-UK and India-EU FTAs for footwear. For personal care, exports to Middle East (UAE, Saudi Arabia) discussions put on hold due to geopolitical crisis. Dr. Scholl's portfolio already exported to UK, EU, Australia, NZ, Japan. Class 3 medical devices certification in progress at Chennai for EU/UK exports. (Sameer Kothari, Ganesh Argekar)

GST Inversion & Contract Negotiations

• Question: Can HFL negotiate better ROCE/ROE terms or equity funding from customers given GST inversion and weakening competition? Any asset revaluation plans? (Faisal Hawa)
• Answer: Backward integration (cones, sticks) has been successful — existing customers now source from these units and new customers have been added; actively exploring further integration. GST inversion alone isn't a driver for outsourcing decisions, but scale and customer diversification will improve capital-based ratios. No asset revaluation done; assets sit on balance sheet and "will get unlocked at some point." Better terms come from scale and diversity, not GST inversion. (Sameer Kothari)

Gross Block Growth and Pipeline Conversion

• Question: How should we view gross block growth 3-5 years out given past 28% CAGR vs 20% revenue CAGR? What's the pipeline hit ratio? (Rahul)
• Answer: Pipeline of ~₹1,000 crores under discussion; policy is to announce CapEx only after signing. Got burned last quarter when only ₹150 crores was announced but pipeline existed. Hit ratio varies by customer and BU; focus is on execution capability. Company expects to continue investing internally generated funds at 18%+ ROCE threshold without external equity, maintaining 1:1 debt-equity. Due to GST inversion and customer-supplied raw material model, EBITDA/PAT will grow faster than revenue. (Sameer Kothari)

HPC Demand Traction

• Question: Has HPC category demand materially changed vs 3-6 months ago? (Mayur Parkeria)
• Answer: Yes, materially changed. Evidence: record CapEx plans (FY27 will exceed FY26), project pipeline ~₹1,000 crores, increased traction in demand. Home care liquid category witnessing double-digit volume growth nationally, which is a tailwind for HFL. Management remains circumspect given macro ambiguity but is "definitely more bullish" than three months ago. (Sameer Kothari)

Key Takeaway

Hindustan Foods delivered its highest-ever quarterly PAT of ₹42.8 crores (+33% YoY) on revenue of ₹1,207 crores (+18% YoY), with EBITDA of ₹106.3 crores (+26% YoY) despite a ~₹6 crores footwear hit from Middle East crisis-driven raw material inflation and a 30% Haryana minimum wage hike. The company signed ₹340 crores of new CapEx in Q1 (F&B ₹210 cr, ice cream ₹80 cr, HPC ₹50 cr), bringing FY27 total to ~₹500 crores including carry-forward, and disclosed ~₹1,000 crores project pipeline under discussion. Management reaffirmed FY27 PAT guidance of ₹200-220 crores, with footwear order books full from Q2 at 80-90% utilization and beverage capacities aimed for December-January commissioning to capture the season. Strategic focus remains on anchor-tenant capacity underwriting at 18%+ ROCE, backward integration, and disciplined execution of a record CapEx cycle; key risks include US tariff ambiguity stalling personal care exports, GST inversion cash flow drag, and recurring geopolitical/logistical disruptions in footwear sourcing. The company maintains 1:1 debt-equity funding, expects EBITDA/PAT growth to outpace revenue growth structurally, and remains optimistic on sustaining growth into FY28 and beyond.